Autonomic regulation of nasal vessels during changes in body position.
The effects of postural changes on nasal airflow and nasal capillary blood flow were investigated in 15 healthy volunteers. Measurements were performed following nasal application of saline solution (control), the alpha-1 receptor antagonist prazosin, the alpha-2 receptor antagonist yohimbine, and after application of both prazosin and yohimbine. Nasal airflow in the control experiments did not significantly differ in the upright (362 +/- 166 ml/s), dorsally recumbent (350 +/- 167 ml/s) and 70 degrees head down position (311 +/- 167 ml/s). Following application of prazosin, nasal airflow was reduced to 223 +/- 121 ml/s in the upright position. Prazosin treatment significantly reduced nasal airflow to 177 +/- 111 ml/s when subjects were placed in dorsally recumbent positions and to 117 +/- 104 ml/s in 70 degrees head down positions (P < 0.001). Following application of yohimbine, nasal airflow remained stable when subjects were turned from upright (348 +/- 165 ml/s) to supine position (352 +/- 186 ml/s), whereas it was reduced to 199 +/- 137 ml/s in the head-down position. Application of both prazosin and yohimbine significantly increased nasal capillary blood flow in laser Doppler flowmetry measurements (P < 0.05). Changes in body position with or without application of the active drugs did not alter nasal capillary blood flow. These findings suggest that nasal congestion due to increased filling pressure in nasal capacitance vessels following postural changes is mainly prevented by alpha-1 adrenergic mechanisms.
Riechelmann
H
H
Department of Otorhinolaryngology, Johannes Gutenberg University Medical School, Germany.
Krause
W
W
D000281:Administration, Intranasal; D000328:Adult; D000403:Airway Resistance / Q000187:drug effects / Q000502:physiology; D002196:Capillaries / Q000187:drug effects / Q000502:physiology; D018475:Head-Down Tilt / Q000502:physiology; D006801:Humans; D017078:Laser-Doppler Flowmetry; D008833:Microcirculation / Q000187:drug effects / Q000294:innervation; D009666:Nose / Q000098:blood supply* / Q000187:drug effects / Q000502:physiology; D010919:Placebos; D011187:Posture / Q000502:physiology*; D011224:Prazosin / Q000008:administration & dosage / Q000494:pharmacology; D012123:Pulmonary Ventilation / Q000187:drug effects / Q000502:physiology*; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000502:physiology*; D012965:Sodium Chloride; D016683:Supine Position / Q000502:physiology; D015016:Yohimbine / Q000008:administration & dosage / Q000494:pharmacology
D010919:Placebos; D011942:Receptors, Adrenergic, alpha; D015016:Yohimbine; D012965:Sodium Chloride; D011224:Prazosin